Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Therapies
VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium
November 22nd, 2007
At the Society for Biomolecular Sciences (SBS) Stem Cell Symposium today in Anaheim, California, H. Ralph Snodgrass, Ph.D., President and CEO of VistaGen Therapeutics, Inc., will present an overview of the Company's latest embryonic stem (ES) cell-based drug discovery and development advances. VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders. "ES cells provide a clinically relevant biological system that offers a powerful discovery tool for understanding many significant diseases such as cancer,...
Source: Genetics & Environmental Business Week (2007-11-22)
|
